Authors:
JUNGWIRTH A
GOMAHR A
JOOS H
FRICK J
MOOYOUNG AJ
NASH H
SCHLEGEL PN
KUZMA P
BARDIN CW
Citation: A. Jungwirth et al., POTENT LHRH-AGONIST FOR TESTOSTERONE DEPRIVATION (NEW MODE OF APPLICATION), The Journal of urology, 159(5), 1998, pp. 494-494
Authors:
JOOS H
SEDLMAYER F
GOMAHR A
RAHIM HBK
FRICK J
KOGELNIK HD
RETTENBACHER L
Citation: H. Joos et al., ENDOCRINE PROFILES AFTER RADIOTHERAPY IN STAGE-I SEMINOMA - IMPACT OF2 DIFFERENT RADIATION TREATMENT MODALITIES, Radiotherapy and oncology, 43(2), 1997, pp. 159-162
Authors:
GOMAHR A
KUNIT G
JUNGWIRTH A
MACK D
FRICH J
Citation: A. Gomahr et al., INTERNATIONAL-CONFERENCE ON PEYRONIES-DISEASE - ADVANCES IN BASIC ANDCLINICAL RESEARCH, The Journal of urology, 158(6), 1997, pp. 2251-2252
Authors:
HOBARTH K
HALLAS A
STEINER G
GOMAHR A
AULITZKY W
MARBERGER M
Citation: K. Hobarth et al., CIRCULATING IMMUNE MARKERS IN ADVANCED RENAL-CELL CARCINOMA DURING IMMUNOTHERAPY WITH INTERFERON-GAMMA, Urological research, 24(2), 1996, pp. 101-106
Authors:
GASTL G
EBERT T
FINSTAD CL
SHEINFELD J
GOMAHR A
AULITZKY W
BANDER NH
Citation: G. Gastl et al., MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I AND CLASS-II EXPRESSION IN RENAL-CELL CARCINOMA AND MODULATION BY INTERFERON-GAMMA, The Journal of urology, 155(1), 1996, pp. 361-367
Citation: D. Mack et al., NEOPTERIN AS A MONITORING PARAMETER FOR TREATMENT WITH BCG IN SUPERFICIAL BLADDER-CANCER, European journal of cancer, 31A(6), 1995, pp. 1025-1026